Thursday, December 7, 2023
OANDP-L
  • Login
No Result
View All Result
The O&P EDGE
  • PECOS
  • Magazine
    • Subscription
    • Current Issue
    • Issue Archive
    • News Archive
    • Product & Service Directory
    • Advertising Information
    • EDGE Flipbooks
  • O&P Jobs
    • Find a Job
    • Post a Job
  • EDGE Advantage
    • EA Homepage
    • EA Data
  • O&P Facilities
  • Resources
    • Product & Service Directory
    • Calendar
    • Contact
    • About Us
    • O&P Library
    • The Guide
    • Custom Publications
    • Advertising Information
    • EDGE Direct
    • Amplitude Media Group
  • PECOS
  • Magazine
    • Subscription
    • Current Issue
    • Issue Archive
    • News Archive
    • Product & Service Directory
    • Advertising Information
    • EDGE Flipbooks
  • O&P Jobs
    • Find a Job
    • Post a Job
  • EDGE Advantage
    • EA Homepage
    • EA Data
  • O&P Facilities
  • Resources
    • Product & Service Directory
    • Calendar
    • Contact
    • About Us
    • O&P Library
    • The Guide
    • Custom Publications
    • Advertising Information
    • EDGE Direct
    • Amplitude Media Group
No Result
View All Result
The O&P EDGE Magazine
No Result
View All Result
Home News

“Hunger Hormone” May Treat Severe Peripheral Artery Disease

by The O&P EDGE
December 17, 2015
in News
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

A new study by a team of researchers from New Zealand’s University of Otago and Japan suggests that the appetite-regulating hormone ghrelin could be used clinically for the early treatment of critical limb ischemia (CLI), an advanced form of peripheral artery disease (PAD).

CLI is the severe obstruction of blood flow to the extremities that often requires major amputations and in half of all cases leads to death within five years. It is characterized by pain at rest, nonhealing ulcers, and gangrene. Its leading risk factors are diabetes, obesity, and age.

Using a mouse model of CLI, Otago Department of Physiology researchers Rajesh Katare, PhD, Daryl Schwenke, PhD, and colleagues showed that administering ghrelin daily over two weeks markedly improved blood flow in affected limbs.

They found that ghrelin promoted growth of new structurally and functionally normal blood vessels, improved cell survival, and decreased tissue fibrosis.

Their research is published in the international journal Endocrinology.

Katare said the findings are exciting as currently there are no drug treatments for CLI and other techniques are effective in only half of the cases.

“Our results provide a platform for future studies to look at the long-term potential of ghrelin to see if it could indeed become a standard treatment for CLI,” Katare said.

This article was adapted from information provided by the University of Otago.

Related posts:

  1. PLX-PAD: Stem Cell Treatment May Save Limbs
  2. Clinical Study Offers Hope to Critical Limb Ischemia Patients
  3. Diabetic Patient Care: Education+Teamwork = Rx for Success
  4. Poststroke Considerations in AFO Usage
Previous Post

VA Issues National Coverage Policy for ReWalk Exoskeleton

Next Post

In Memoriam: Jerome Paul Voisin

Next Post

In Memoriam: Jerome Paul Voisin

  • VIEW CURRENT ISSUE
  • SUBSCRIBE FOR FREE

RECENT NEWS

News

Thrive Orthopedics Granted Exclusive Rights for Equinus Brace

by The O&P EDGE
December 4, 2023

IQ Med, the holding company of the Equinus Brace, granted Thrive Orthopedics exclusive distribution and manufacturing rights to the device....

Read more

BOC Names New Board, Executive Committee

Risk Factors for Phantom Limb Pain Identified

Prosthetic Design Studio Marks Milestone

Get unlimited access!

Join EDGE ADVANTAGE and unlock The O&P EDGE's vast library of archived content.
SUBSCRIBE TODAY

O&P JOBS

Central

Orthotist Assistant

Eastern

Certified Pedorthist

Central

Clinical Manager

 

© 2023 The O&P EDGE

  • About
  • Advertise
  • Contact
  • EDGE Advantage
  • OANDP-L
  • Subscribe

CONTACT US

866-613-0257

[email protected]

201 E. 4th St
Loveland, CO 80537

The most important industry news and events delivered directly to your inbox every week.

  • About
  • Advertise
  • Contact
  • EDGE Advantage
  • OANDP-L
  • Subscribe

© 2023 The O&P EDGE

No Result
View All Result
  • PECOS
  • MAGAZINE
    • SUBSCRIBE
    • CURRENT ISSUE
    • ISSUE ARCHIVE
    • NEWS ARCHIVE
    • PRODUCTS & SERVICES DIRECTORY
    • ADVERTISING INFORMATION
  • O&P JOBS
    • FIND A JOB
    • POST A JOB
  • EDGE ADVANTAGE
    • EA Homepage
    • EA Data
  • FACILITIES
  • RESOURCES
    • PRODUCTS & SERVICES DIRECTORY
    • CALENDAR
    • CONTACT
    • ABOUT US
    • O&P LIBRARY
    • THE GUIDE
    • CUSTOM PUBLICATIONS
    • ADVERTISING
    • EDGE DIRECT
    • AMPLITUDE
  • OANDP-L
  • LOGIN

© 2023 The O&P EDGE

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
The O&P EDGE Magazine
 
Required 'Candidate' login to applying this job. Click here to logout And try again
 

Login to your account

  • Forgot Password? | Sign Up

Reset Password

  • Already have an account? Login

Enter the username or e-mail you used in your profile. A password reset link will be sent to you by email.

Signup to your Account

  • By clicking checkbox, you agree to our Terms and Conditions and Privacy Policy

    Already have an account? Login

Close
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
 

Account Activation

Before you can login, you must activate your account with the code sent to your email address. If you did not receive this email, please check your junk/spam folder. Click here to resend the activation email. If you entered an incorrect email address, you will need to re-register with the correct email address.